1. Home
  2. ADAG vs CFBK Comparison

ADAG vs CFBK Comparison

Compare ADAG & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$4.01

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$34.36

Market Cap

231.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
CFBK
Founded
2011
1892
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
260.3M
231.8M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
ADAG
CFBK
Price
$4.01
$34.36
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$8.25
$31.50
AVG Volume (30 Days)
290.4K
58.1K
Earning Date
04-01-2026
05-08-2026
Dividend Yield
N/A
1.23%
EPS Growth
N/A
30.58
EPS
N/A
1.67
Revenue
N/A
N/A
Revenue This Year
N/A
$31.99
Revenue Next Year
N/A
$9.09
P/E Ratio
N/A
$20.72
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$22.10
52 Week High
$4.85
$36.95

Technical Indicators

Market Signals
Indicator
ADAG
CFBK
Relative Strength Index (RSI) 56.54 49.96
Support Level $3.23 $32.20
Resistance Level $4.41 $36.82
Average True Range (ATR) 0.29 0.79
MACD 0.03 -0.30
Stochastic Oscillator 64.10 22.39

Price Performance

Historical Comparison
ADAG
CFBK

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

Share on Social Networks: